Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against TriSalus Life Sciences, Inc. (TLSI) and Encourages Stockholders to Learn More About the Investigation

NEW YORK CITY, NY / ACCESS Newswire / May 25, 2026 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of TriSalus Life Sciences, Inc. ("TriSalus" or "the Company") (NASDAQ:TLSI). Investors who purchased TriSalus securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/TLSI.

TriSalus Investigation Details

On May 12, 2026, TriSalus reported first quarter results, including revenue of $8.90M, a decline of 2.92% year over year. The Company further announced a cut to full year revenue guidance to $54 million to $57, a cut of $5.5 million at the midpoint compared to prior guidance. In the accompanying earnings call, management explained "the driver of this revision includes both the lower Q1 revenues from the commercial expansion and the delayed FDA clearance timing for TriNav Advance." Management further stated FDA clearance for TriNav Advance "is now running approximately 5 months past the 30-day MDUFA review goal." Following this news, the price of the Company's stock dropped.

What's Next for TriSalus Investors?

If you are aware of any facts relating to this investigation or purchased TriSalus securities, you can assist this investigation by visiting the firm's site: bgandg.com/TLSI. You can also contact Peretz Bronstein or his client relations manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC: 917-590-0911

No Cost to TriSalus Investors

We, Bronstein, Gewirtz & Grossman, LLC, represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys' fees, usually a percentage of the total recovery, only if we are successful.

Why Bronstein, Gewirtz & Grossman, LLC for TriSalus Securities Investigation?

Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.

"Our practice centers on restoring investor capital and ensuring corporate accountability, which serves to uphold the essential integrity of the marketplace," said Peretz Bronstein, Founding Partner of Bronstein, Gewirtz & Grossman, LLC.

Contact Info

Peretz Bronstein, Esq. or Nathan Miller

Bronstein, Gewirtz & Grossman, LLC

917-590-0911 | [email protected]

Attorney advertising.

Prior results do not guarantee similar outcomes.

SOURCE: Bronstein, Gewirtz & Grossman, LLC